Literature DB >> 29198035

Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.

Jamilla Li1, Joycelyn Sim1, Anskar Y H Leung1, Yok-Lam Kwong2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29198035     DOI： 10.1007/s00277-017-3179-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

1.  Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.

Authors:  Toshiki Terao; Junichiro Yuda; Nobuhiko Yamauchi; Yong-Mei Guo; Kaoru Shimada; Masato Sugano; Genichiro Ishii; Yosuke Minami
Journal:  Mol Clin Oncol       Date:  2021-04-23

2.  Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone).

Authors:  Sundar V Cherukuri; Amit Sureen; Taylor Infante; Nevetha Rajendran; Osvaldo Padilla; Sumit Gaur
Journal:  Cureus       Date:  2021-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.